Latest filings (excl ownership)
8-K
Agile Therapeutics Announces Delisting from Nasdaq
25 Mar 24
8-K
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
14 Mar 24
424B5
Prospectus supplement for primary offering
23 Feb 24
424B5
Prospectus supplement for primary offering
23 Feb 24
8-K
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
23 Feb 24
8-K
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
15 Feb 24
S-1/A
IPO registration (amended)
7 Feb 24
S-1/A
IPO registration (amended)
5 Feb 24
S-1/A
IPO registration (amended)
2 Feb 24
S-1/A
IPO registration (amended)
20 Dec 23
S-1
IPO registration
11 Dec 23
8-K
Other Events
6 Dec 23
8-K
Entry into a Material Definitive Agreement
4 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Oct 23
8-K
Entry into a Material Definitive Agreement
28 Sep 23
8-K/A
Departure of Directors or Certain Officers
22 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
9 Aug 23
8-K
Departure of Directors or Certain Officers
30 Jun 23
8-K
Departure of Directors or Certain Officers
27 Jun 23
8-K/A
Departure of Directors or Certain Officers
14 Jun 23
S-8
Registration of securities for employees
9 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Jun 23
8-K
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
25 May 23
424B5
Prospectus supplement for primary offering
25 May 23
424B5
Prospectus supplement for primary offering
25 May 23
424B5
Prospectus supplement for primary offering
25 May 23
424B4
Prospectus supplement with pricing info
24 May 23
EFFECT
Notice of effectiveness
23 May 23
S-1/A
IPO registration (amended)
19 May 23
CORRESP
Correspondence with SEC
19 May 23
CORRESP
Correspondence with SEC
19 May 23
8-K
Other Events
17 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Agile Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
11 May 23
8-K
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
Latest ownership filings
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
Scott M Coiante
4 Oct 23
3
Scott M Coiante
25 Aug 23
4
Amy Welsh
30 Jun 23
4
Paul Korner
30 Jun 23
4
ALFRED ALTOMARI
30 Jun 23
4
Robert G Conway
30 Jun 23
4
Geoffrey Gilmore
30 Jun 23
4
Josephine Torrente
9 Jun 23
4
Seth H. Z. Fischer
9 Jun 23
4
John W Hubbard
9 Jun 23
4
Sandra Carson
9 Jun 23
4
SHARON BARBARI
9 Jun 23
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 23
SC 13G/A
Lind Global Fund II LP
13 Feb 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
Amy Welsh
14 Nov 22
4
Jason Butch
14 Nov 22
4
Paul Korner
14 Nov 22
4
ALFRED ALTOMARI
14 Nov 22
4
Robert G Conway
14 Nov 22
4
Geoffrey Gilmore
14 Nov 22
3
Amy Welsh
9 Nov 22
4
ALFRED ALTOMARI
29 Aug 22
SC 13G
Lind Global Fund II LP
12 Jul 22
SC 13G
INTRACOASTAL CAPITAL, LLC
11 Jul 22
4
SHARON BARBARI
10 Jun 22
4
Sandra Carson
10 Jun 22
4
Seth H. Z. Fischer
10 Jun 22
4
John W Hubbard
10 Jun 22
4
Ajit Shetty
10 Jun 22
4
James Patrick Tursi
10 Jun 22
4
Josephine Torrente
10 Jun 22
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 22
SC 13G/A
VANGUARD GROUP INC
9 Feb 22
4
Dennis Reilly
20 Jan 22
4
Jason Butch
20 Jan 22
4
Geoffrey Gilmore
20 Jan 22
4
ALFRED ALTOMARI
20 Jan 22